Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berdazimer sodium - SB 204 - Novan

Drug Profile

Berdazimer sodium - SB 204 - Novan

Alternative Names: MAP3-NONOate - SB-204; NVN1000-SB204; SB-204

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Propylamines; Silicon compounds; Skin disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Discontinued Staphylococcal infections

Most Recent Events

  • 09 Sep 2021 Phase III development for Acne vulgaris (In adolescents, In adults, In children, In the elderly) is still ongoing in USA (Topical,Gel) (Novan's pipeline, September 2021)
  • 09 Sep 2021 Novan announces intention to submit NDA to US FDA for Acne vulgaris in 2024
  • 09 Sep 2021 Novan plans a pivotal phase III trial for Acne vulgaris in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top